Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,622 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 6,622 shares of Maplight Therapeutics stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $18.12, for a total transaction of $119,990.64. Following the transaction, the director owned 351,611 shares in the company, valued at approximately $6,371,191.32. This trade represents a 1.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Maplight Therapeutics Stock Performance

Shares of MPLT stock traded down $0.55 on Thursday, hitting $17.22. The company had a trading volume of 129,264 shares, compared to its average volume of 191,375. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $21.55. The stock has a market cap of $781.27 million and a price-to-earnings ratio of -0.46. The company’s 50-day moving average price is $18.20.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Institutional Investors Weigh In On Maplight Therapeutics

Several large investors have recently made changes to their positions in the business. Strs Ohio bought a new position in Maplight Therapeutics during the fourth quarter valued at about $53,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics in the fourth quarter valued at about $93,000. MetLife Investment Management LLC purchased a new position in Maplight Therapeutics in the fourth quarter valued at about $172,000. Deutsche Bank AG bought a new position in shares of Maplight Therapeutics during the 4th quarter valued at approximately $210,000. Finally, Nuveen LLC purchased a new stake in shares of Maplight Therapeutics during the 4th quarter worth approximately $355,000.

Analyst Upgrades and Downgrades

MPLT has been the topic of a number of research reports. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price target on the stock. Wall Street Zen upgraded Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Stifel Nicolaus started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $28.00 target price on the stock. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 target price on the stock. Finally, Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.